IS 159

Drug Profile

IS 159

Latest Information Update: 12 Feb 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immunotech
  • Developer Immunotech; The Medicines Company
  • Class Antimigraines; Small molecules
  • Mechanism of Action Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Migraine

Most Recent Events

  • 12 Feb 2003 Discontinued - Phase-II for Migraine in France (Intranasal)
  • 12 Feb 2003 Discontinued - Phase-II for Migraine in USA (Intranasal)
  • 06 Mar 2001 A study in volunteers has been added to the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top